1-20 of 30
John C. Byrd
Close
Sort by
Articles

Immune Whispering: Safely Harnessing the GVL Effect Using Vaccination

John C. Byrd, MD, Jason A. Dubovsky, PhD
Journal: The Hematologist
The Hematologist (2013) 10 (6)
https://doi.org/10.1182/hem.V10.6.1016
Published: 2013
Articles

Genetic Evolution Promotes Progression and Drives Relapse in CLL

Yiming Zhong, PhD, John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2013) 10 (5)
https://doi.org/10.1182/hem.V10.5.1031
Published: 2013
Articles

Ibrutinib for del(17p13.1) CLL Patients: A Potential Bonanza

Sam Penza, MD, John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2013) 10 (2)
https://doi.org/10.1182/hem.V10.2.1073
Published: 2013
Articles

Refining our Understanding of the Genetic Variation in CLL

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2013) 10 (1)
https://doi.org/10.1182/hem.V10.1.1089
Published: 2013
Articles

B10 Cells and Immune Suppression in CLL

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2012) 9 (6)
https://doi.org/10.1182/hem.V9.6.1112
Published: 2012
Articles

More Therapeutic Antibody May Not Always Be Better

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2012) 9 (5)
https://doi.org/10.1182/hem.V9.5.1130
Published: 2012
Articles

Standard of Care for Treating Older Patients with Chronic Lymphocytic Leukemia

John C. Byrd, MD, Deborah M. Stephens, DO
Journal: The Hematologist
The Hematologist (2012) 9 (4)
https://doi.org/10.1182/hem.V9.4.1146
Published: 2012
Articles

Epigenetic Therapy for Elderly Patients With AML

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2012) 9 (3)
https://doi.org/10.1182/hem.V9.3.1153
Published: 2012
Articles

Lymphocytosis and B-Cell Receptor Antagonists in CLL

John C. Byrd, MD, Amy J. Johnson, PhD
Journal: The Hematologist
The Hematologist (2012) 9 (2)
Published: 2012
Articles

The Value of Specialty Care in Malignant Hematology

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2012) 9 (1)
https://doi.org/10.1182/hem.V9.1.1192
Published: 2012
Articles

CLL Whole-Genomic Sequencing Notches Up Our Understanding of the Disease

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2011) 8 (5)
https://doi.org/10.1182/hem.V8.5.1233
Published: 2011
Articles

MicroRNAs in the Plasma: Not miRly a New Biomarker

John C. Byrd, MD, Erin HertleIn, PhD
Journal: The Hematologist
The Hematologist (2011) 8 (4)
https://doi.org/10.1182/hem.V8.4.1247
Published: 2011
Articles

Richter's Transformation Finds an Identity

John C. Byrd, MD, Lapo Alinari, MD
Journal: The Hematologist
The Hematologist (2011) 8 (3)
https://doi.org/10.1182/hem.V8.3.1265
Published: 2011
Articles

Investigation of Novel Initial Therapy for Chronic Lymphocytic Leukemia

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2011) 8 (3)
https://doi.org/10.1182/hem.V8.3.1278
Published: 2011
Articles

CT Scans in Response and Follow-Up Assessment of CLL: Can We Eliminate Their Use?

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2011) 8 (2)
https://doi.org/10.1182/hem.V8.2.6309
Published: 2011
Articles

Rituximab Chemoimmunotherapy Transforms Old Treatment Paradigms for CLL by Improving Overall Survival

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2011) 8 (1)
https://doi.org/10.1182/hem.V8.1.6317
Published: 2011
Articles

P53 Mutational Analysis: Another Necessary Biomarker in CLL?

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2010) 7 (6)
https://doi.org/10.1182/hem.V7.6.6265
Published: 2010
Articles

Chronic Lymphocytic Leukemia

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2010) 7 (5)
https://doi.org/10.1182/hem.V7.5.6225
Published: 2010
Articles

Targeting CD20: Still Much to Learn

Jonathan Butchar, PhD, John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2010) 7 (4)
https://doi.org/10.1182/hem.V7.4.6335
Published: 2010
Articles

The Elusive Leukemia Stem Cell

John C. Byrd, MD
Journal: The Hematologist
The Hematologist (2010) 7 (4)
https://doi.org/10.1182/hem.V7.4.6279
Published: 2010